Engineered virus targets HIV-infected cells: interview with Garry Nolan, Ph.D. Interview by John S. James.
Nolan
G
G
D019380:Anti-HIV Agents / Q000008:administration & dosage; D015704:CD4 Antigens / Q000378:metabolism; D005818:Genetic Engineering; D015658:HIV Infections / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008081:Liposomes; D011820:Rabies virus / Q000235:genetics*; D019718:Receptors, CXCR4 / Q000378:metabolism; D012747:Sexual Partners; D015229:Sexually Transmitted Diseases, Viral / Q000821:virology; D014721:Vesicular stomatitis Indiana virus / Q000235:genetics*; D014779:Virus Replication
D019380:Anti-HIV Agents; D015704:CD4 Antigens; D008081:Liposomes; D019718:Receptors, CXCR4